Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation, and our belief that by acting with integrity in an honest, respectful, ethical manner, we have the power to change lives. Our workplace embodies collaboration, open communication, celebrating our successes and holding each other to the highest possible standards.
CytomX embraces diversity and seeks to enhance and maintain our culture of equity and inclusion which encourages individuals to be themselves, feel involved, respected and connected.
We at CytomX believe that we benefit from each other’s ideas and experiences. We accept our differences and learn from one another, improve together, and embrace change to achieve our corporate and individual objectives. This belief applies to how we work together at CytomX, how we work with others outside CytomX, how we represent CytomX in our communities, and how we endeavor to bring our scientific innovations to a diverse patient population.
CytomX acknowledges the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. CytomX is an equal opportunity employer and does not discriminate against any individual or potential candidate because of race, color, religion, sex, national origin, sexual preference or any other legally protected category.
CytomX is located in South San Francisco, California, the birthplace of biotechnology. Learn more about us and how we are advancing science to treat cancer differently at www.cytomX.com.
Overview
Investors 4
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| ATEL Capital Group | atel.com | |
| Jul 10, 2026 | Longitude Capital | longitudecapital.com |
| Canaan Partners | canaan.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Jan 6, 2015 | Series C round | $20M | |
| Sep 23, 2010 | Series B round | $30M |
Mentions in press and media 25
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 8, 2024 | CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | - CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 - - Phase 1 clinical study of CX-2051, an EpCAM targeting PROBODY® ADC, is on... |
| Mar 11, 2024 | CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update | |
| Mar 11, 2024 | CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update | - CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase 1 clinical study initiation in solid tumors, including colorectal cancer (CRC) antici... |
| Jan 5, 2023 | Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics | Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million upfront payment with the potential for addition... |
| Nov 4, 2021 | CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update - Form 8-K | CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update -Initial data release from Phase 2 study of CX-2029 remains on track for fourth quarter 2021- -Initial data release from Phase 2 study of praluz... |
| Aug 5, 2021 | CytomX Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update | SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therape... |
| May 6, 2021 | CYTOMX THERAPEUTICS, INC. CytomX Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update | SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeu... |
| Sep 23, 2020 | Endpoints News: A longtime CytomX exec re-emerges at Synthekine, an $82M Stanford spinout | |
| Mar 20, 2017 | A small drug company that's trying to make cancer treatments safer just received a huge endorsement | REUTERS/Suzanne Plunkett A tray containing cancer cells sits on an optical microscope in the Nanomedicine Lab at UCL's School of Pharmacy in London. CytomX, a biotech that's developing safer ways to administer cancer immunotherapies, just g... |
Reviews 0
FAQ about CytomX Therapeutics
When was CytomX Therapeutics founded?
CytomX Therapeutics was founded in 2008.
How much funding has CytomX Therapeutics raised?
CytomX Therapeutics has raised $120M in total across 3 funding rounds.
What funding rounds has CytomX Therapeutics raised?
Parsers VC lists 3 funding rounds of CytomX Therapeutics, among them a Series C round of $20M on Jan 6, 2015 and a Series B round of $30M on Sep 23, 2010.
Who has invested in CytomX Therapeutics?
Parsers VC lists 4 investors of CytomX Therapeutics, among them Longitude Capital, ATEL Capital Group and Canaan Partners.
What has the press written about CytomX Therapeutics?
Parsers VC has collected 25 articles mentioning CytomX Therapeutics, among them “CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update” (Aug 8, 2024) and “CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update” (Mar 11, 2024).
Is CytomX Therapeutics still active?
Yes, CytomX Therapeutics is active; its latest activity on Parsers VC dates from Jul 10, 2026.